Ribociclib Succinate is Used for treating HR-positive, HER2-negative advanced or metastatic breast cancer in combination with other endocrine-based therapies. It was first introduced by Novartis Pharmaceuticals Corp in its drug Kisqali on Mar 13, 2017.

Ribociclib Succinate Patents

Given below is the list of patents protecting Ribociclib Succinate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Kisqali	US10799506	Ribociclib tablet	Apr 14, 2036	Novartis
Kisqali	US8324225	Pyrrolopyrimidine compounds and their uses	Jun 17, 2028	Novartis
Kisqali	US8415355	Pyrrolopyrimidine compounds and their uses	Mar 13, 2031	Novartis
Kisqali	US8685980	Pyrrolopyrimidine compounds and their uses	May 25, 2030	Novartis
Kisqali	US8962630	Pyrrolopyrimidine compounds and their uses	Dec 09, 2029	Novartis
Kisqali	US9193732	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	Nov 09, 2031	Novartis
Kisqali	US9416136	Pyrrolopyrimidine compounds and their uses	Aug 20, 2029	Novartis
Kisqali	US9868739	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	Nov 09, 2031	Novartis

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳